Hubei Biocause Heilen Pharmaceutical (301211.SZ): approval of market application for gefitinib hydrochloride chemical raw material drug.

15:55 03/02/2026

Hendy Pharmaceutical (301211.SZ) announced that the company has recently received the "Approval Notice for the Application for Market Approval of Chemical Raw Materials for Enoxatin Hydrochloride" issued by the National Medical Products Administration.

Hubei Biocause Heilen Pharmaceutical (301211.SZ) announced that the company has recently received the "Chemical Raw Material Drug Marketing Application Approval Notice" for the approval of Erlotinib Hydrochloride issued by the National Medical Products Administration. It is reported that Erlotinib Hydrochloride is an EGFR tyrosine kinase inhibitor targeted drug, mainly used to treat locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the epidermal growth factor receptor (EGFR) gene. It can also be used for the treatment of patients with advanced non-small cell lung cancer who have failed prior chemotherapy.

Yum China (09987) spent 773.98 million Hong Kong dollars to repurchase 20,100 shares on February 2nd.

As of the end of January, Lens Technology (06613) has repurchased approximately 7.4096 million A-shares.

Shanxi Install (02520) and Shanghai Jingyu have reached a joint venture agreement with Shanxi Infrastructure to establish a joint venture company to invest in a BOO project.

Yum China (09987) spent 773.98 million Hong Kong dollars to repurchase 20,100 shares on February 2nd.

As of the end of January, Lens Technology (06613) has repurchased approximately 7.4096 million A-shares.

Shanxi Install (02520) and Shanghai Jingyu have reached a joint venture agreement with Shanxi Infrastructure to establish a joint venture company to invest in a BOO project.